Sinovac Biotech (SVA) Competitors

$6.47 0.00 (0.00%)

As of 05/4/2026

SVA vs. NTLA, PGEN, DMRA, IMCR, and BCAX

Should you be buying Sinovac Biotech stock or one of its competitors? The main competitors of Sinovac Biotech include Intellia Therapeutics (NTLA), Precigen (PGEN), Damora Therapeutics, Inc. Common Stock (DMRA), Immunocore (IMCR), and Bicara Therapeutics (BCAX). These companies are all part of the "med - biomed/gene" industry.

How does Sinovac Biotech compare to Intellia Therapeutics?

Sinovac Biotech (NASDAQ:SVA) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

: Sinovac Biotech has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500.
: Sinovac Biotech has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -609.85%. Sinovac Biotech's return on equity of 0.00% beat Intellia Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Sinovac Biotech N/A N/A N/A
Intellia Therapeutics -609.85% -56.81% -45.34%
: In the previous week, Intellia Therapeutics had 14 more articles in the media than Sinovac Biotech. MarketBeat recorded 16 mentions for Intellia Therapeutics and 2 mentions for Sinovac Biotech. Intellia Therapeutics' average media sentiment score of 0.48 beat Sinovac Biotech's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sinovac Biotech
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Intellia Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 88.8% of Intellia Therapeutics shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by company insiders. Comparatively, 3.1% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: Intellia Therapeutics has a consensus price target of $20.09, suggesting a potential upside of 50.92%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Sinovac Biotech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Intellia Therapeutics
3 Sell rating(s)

10 Hold rating(s)

9 Buy rating(s)

1 Strong Buy rating(s)
2.35
: Sinovac Biotech has higher revenue and earnings than Intellia Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sinovac Biotech $361.37M 1.78 $90.90M N/A N/A
Intellia Therapeutics $67.67M 23.69 -$412.69M -$3.83 N/A

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Intellia Therapeutics	-609.85%	-56.81%	-45.34%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$361.37M	1.78	$90.90M	N/A	N/A
Intellia Therapeutics	$67.67M	23.69	-$412.69M	-$3.83	N/A

Summary

Intellia Therapeutics beats Sinovac Biotech on 9 of the 15 factors compared between the two stocks.

How does Sinovac Biotech compare to Precigen?

Sinovac Biotech (NASDAQ:SVA) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

: Sinovac Biotech has a net margin of 0.00% compared to Precigen's net margin of -2,588.21%. Precigen's return on equity of 2,317.96% beat Sinovac Biotech's return on equity.
Company Net Margins Return on Equity Return on Assets
Sinovac Biotech N/A N/A N/A
Precigen -2,588.21% 2,317.96% 49.65%
: Precigen has a consensus price target of $9.50, indicating a potential upside of 119.40%. Given Precigen's stronger consensus rating and higher probable upside, analysts plainly believe Precigen is more favorable than Sinovac Biotech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Precigen
1 Sell rating(s)

2 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.43
: Sinovac Biotech has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Precigen has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.
: In the previous week, Precigen had 3 more articles in the media than Sinovac Biotech. MarketBeat recorded 5 mentions for Precigen and 2 mentions for Sinovac Biotech. Precigen's average media sentiment score of 0.64 beat Sinovac Biotech's score of 0.00 indicating that Precigen is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sinovac Biotech
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Precigen
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 33.5% of Precigen shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by company insiders. Comparatively, 47.1% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Sinovac Biotech has higher revenue and earnings than Precigen.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sinovac Biotech $361.37M 1.78 $90.90M N/A N/A
Precigen $9.68M 159.47 -$250.64M -$1.34 N/A

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Precigen	-2,588.21%	2,317.96%	49.65%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Precigen	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precigen	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$361.37M	1.78	$90.90M	N/A	N/A
Precigen	$9.68M	159.47	-$250.64M	-$1.34	N/A

Summary

Precigen beats Sinovac Biotech on 11 of the 14 factors compared between the two stocks.

How does Sinovac Biotech compare to Damora Therapeutics, Inc. Common Stock?

Sinovac Biotech (NASDAQ:SVA) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

: Sinovac Biotech has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sinovac Biotech $361.37M 1.78 $90.90M N/A N/A
Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$12.10 N/A
: Sinovac Biotech has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.
: 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by company insiders. Comparatively, 10.5% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: In the previous week, Sinovac Biotech and Sinovac Biotech both had 2 articles in the media. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.02 beat Sinovac Biotech's score of 0.00 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sinovac Biotech
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Damora Therapeutics, Inc. Common Stock
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Sinovac Biotech's return on equity of 0.00% beat Damora Therapeutics, Inc. Common Stock's return on equity.
Company Net Margins Return on Equity Return on Assets
Sinovac Biotech N/A N/A N/A
Damora Therapeutics, Inc. Common Stock N/A -147.05% -279.49%
: Damora Therapeutics, Inc. Common Stock has a consensus target price of $43.40, indicating a potential upside of 74.51%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Sinovac Biotech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Damora Therapeutics, Inc. Common Stock
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

2 Strong Buy rating(s)
2.88

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$361.37M	1.78	$90.90M	N/A	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$12.10	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Damora Therapeutics, Inc. Common Stock	N/A	-147.05%	-279.49%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Damora Therapeutics, Inc. Common Stock beats Sinovac Biotech on 7 of the 12 factors compared between the two stocks.

How does Sinovac Biotech compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Sinovac Biotech (NASDAQ:SVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

: Immunocore presently has a consensus target price of $60.89, suggesting a potential upside of 111.13%. Given Immunocore's stronger consensus rating and higher possible upside, research analysts plainly believe Immunocore is more favorable than Sinovac Biotech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunocore
2 Sell rating(s)
3 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.36
Sinovac Biotech
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, Immunocore had 3 more articles in the media than Sinovac Biotech. MarketBeat recorded 5 mentions for Immunocore and 2 mentions for Sinovac Biotech. Immunocore's average media sentiment score of 0.28 beat Sinovac Biotech's score of 0.00 indicating that Immunocore is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immunocore
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Sinovac Biotech
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Sinovac Biotech has lower revenue, but higher earnings than Immunocore.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immunocore $400.02M 3.65 -$35.51M -$0.70 N/A
Sinovac Biotech $361.37M 1.78 $90.90M N/A N/A
: Immunocore has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Sinovac Biotech has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
: Sinovac Biotech has a net margin of 0.00% compared to Immunocore's net margin of -8.88%. Sinovac Biotech's return on equity of 0.00% beat Immunocore's return on equity.
Company Net Margins Return on Equity Return on Assets
Immunocore -8.88% -9.20% -3.32%
Sinovac Biotech N/A N/A N/A
: 84.5% of Immunocore shares are owned by institutional investors. 10.4% of Immunocore shares are owned by insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.65	-$35.51M	-$0.70	N/A
Sinovac Biotech	$361.37M	1.78	$90.90M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-8.88%	-9.20%	-3.32%
Sinovac Biotech	N/A	N/A	N/A

Summary

Immunocore beats Sinovac Biotech on 8 of the 14 factors compared between the two stocks.

How does Sinovac Biotech compare to Bicara Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and Sinovac Biotech (NASDAQ:SVA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

: In the previous week, Bicara Therapeutics and Bicara Therapeutics both had 2 articles in the media. Sinovac Biotech's average media sentiment score of 0.00 beat Bicara Therapeutics' score of -0.04 indicating that Sinovac Biotech is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bicara Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Sinovac Biotech
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Sinovac Biotech has higher revenue and earnings than Bicara Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bicara Therapeutics N/A N/A -$137.95M -$2.53 N/A
Sinovac Biotech $361.37M 1.78 $90.90M N/A N/A
: Bicara Therapeutics presently has a consensus price target of $28.00, indicating a potential upside of 20.90%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicara Therapeutics is more favorable than Sinovac Biotech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicara Therapeutics
1 Sell rating(s)
3 Hold rating(s)

8 Buy rating(s)

0 Strong Buy rating(s)
2.58
Sinovac Biotech
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Sinovac Biotech's return on equity of 0.00% beat Bicara Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Bicara Therapeutics N/A -32.49% -30.87%
Sinovac Biotech N/A N/A N/A
: Bicara Therapeutics has a beta of -0.57, suggesting that its share price is 157% less volatile than the S&P 500. Comparatively, Sinovac Biotech has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.53	N/A
Sinovac Biotech	$361.37M	1.78	$90.90M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-32.49%	-30.87%
Sinovac Biotech	N/A	N/A	N/A

Summary

Sinovac Biotech beats Bicara Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Sinovac Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVA vs. The Competition

Export

Metric	Sinovac Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$644.66M	$3.40B	$6.25B	$11.77B
Dividend Yield	N/A	2.23%	2.74%	5.26%
P/E Ratio	N/A	38.57	29.25	27.07
Price / Sales	1.78	280.78	504.14	75.42
Price / Cash	3.19	125.06	43.30	53.90
Price / Book	N/A	7.05	9.67	6.69
Net Income	$90.90M	$23.62M	$3.55B	$332.64M
7 Day Performance	N/A	3.67%	1.70%	2.01%
1 Month Performance	N/A	7.17%	5.62%	9.19%
1 Year Performance	N/A	67.04%	34.42%	39.59%

Sinovac Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVA Sinovac Biotech	N/A	$6.47 flat	N/A	N/A	$644.66M	$361.37M	N/A	3,261	High Trading Volume
NTLA Intellia Therapeutics	2.8216 of 5 stars	$12.44 -5.8%	$20.09 +61.5%	N/A	$1.47B	$67.67M	N/A	600	Analyst Revision Gap Up High Trading Volume
PGEN Precigen	3.2322 of 5 stars	$4.12 +2.5%	$9.50 +130.6%	N/A	$1.46B	$9.68M	N/A	190
DMRA Damora Therapeutics, Inc. Common Stock	2.6118 of 5 stars	$23.93 -1.2%	$43.40 +81.4%	N/A	$1.44B	N/A	N/A	40	Positive News Gap Down
IMCR Immunocore	3.0812 of 5 stars	$27.92 -3.0%	$60.89 +118.1%	N/A	$1.42B	$400.02M	N/A	320	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVA) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sinovac Biotech (SVA) Competitors

SVA vs. NTLA, PGEN, DMRA, IMCR, and BCAX

How does Sinovac Biotech compare to Intellia Therapeutics?

Summary

How does Sinovac Biotech compare to Precigen?

Summary

How does Sinovac Biotech compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Sinovac Biotech compare to Immunocore?

Summary

How does Sinovac Biotech compare to Bicara Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sinovac Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sinovac Biotech (SVA) Competitors

SVA vs. NTLA, PGEN, DMRA, IMCR, and BCAX

How does Sinovac Biotech compare to Intellia Therapeutics?

Summary

How does Sinovac Biotech compare to Precigen?

Summary

How does Sinovac Biotech compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Sinovac Biotech compare to Immunocore?

Summary

How does Sinovac Biotech compare to Bicara Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sinovac Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools